Maze Therapeutics
MAZE
162 hedge funds and large institutions have $1.75B invested in Maze Therapeutics in 2026 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 66 increasing their positions, 38 reducing their positions, and 39 closing their positions.
74% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 38
13% more capital invested
Capital invested by funds: $1.54B → $1.75B (+$203M)
1.8% more ownership
Funds ownership: 103.96% → 105.76% (+1.8%)
2% more call options, than puts
Call options by funds: $2.05M | Put options by funds: $2.01M
0% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 39
2% less funds holding
Funds holding: 165 → 162 (-3)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$68.2M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$29.9M |
| 3 |
BlackRock
New York
|
+$24.4M |
| 4 |
JP Morgan Chase
New York
|
+$23.7M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$19.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$81.9M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$24.4M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$22.4M |
| 4 |
CP
Caligan Partners
New York
|
-$18.4M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$11.6M |
MAZE Hedge Fund Activity: Q2 2026 in Review
162 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Maze Therapeutics (MAZE) for Q2 2026, worth a combined $1.75B — up 13% from $1.54B a quarter earlier.
Fund positioning in MAZE was balanced in Q2 2026: 39 funds opened new positions, 39 closed out, 66 added to existing stakes and 38 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $68.2M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $81.9M sold.
- 162 institutional investors held Maze Therapeutics (MAZE) as of Q2 2026, down from 165 in Q1 2026.
- Funds reported $1.75B of Maze Therapeutics stock for Q2 2026, up 13% quarter-over-quarter.
- 39 funds opened new Maze Therapeutics positions in Q2 2026 and 39 closed out, a net change of 0 holders.
- The largest Maze Therapeutics buyer in Q2 2026 was T. Rowe Price Investment Management, an estimated $68.2M added.
- The largest Maze Therapeutics seller in Q2 2026 was Paradigm Biocapital Advisors, an estimated $81.9M sold.
Based on aggregated 13F filings for Q2 2026.